Longeveron Inc. (LGVN) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Longevity 2025 Full Year Financial Results and Business Update. At this time, all participants are on a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference call is being recorded. I would now like to introduce your host, Jenny Coben. Thank you, you may begin. Good afternoon, everyone, and thank you for joining us today to review Longevron's 2025 full-year financial results and business updates. After the U.S. markets closed today, we issued a press release with the financial results for 2025, which can be found under the Investors section of the Longevron website. On the call today are Stephen Willard, Chief Executive Officer, Joshua Hare, Co-Founder, Chief Science Officer and Executive Chairman of the Board, Natalia Agafanova, Chief Medical Officer, and Lisa Locklear, Chief Financial Officer. As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in the company's filings with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the call to questions from covering analysts. With that, let me hand the call over to Stephen Willard, CEO. Steve? Thank you, Jenny, and thank you all for joining us today. I am excited and honored to join Longeviron at this pivotal moment for the company. The strength of the...